Denileukin diftitox clinical trials
Also written ONTAK, E7777 and DAB389IL-2.
How each study uses denileukin diftitox is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 5 Feb 1999 · ONTAK · BLA 103767 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
39 studies that test it; most in 2005 (8)
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1999 | 2 |
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 4 |
| 2005 | 8 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 4 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2013 | 1 |
| 2016 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 14 · Other 25
Eisai Inc. (10) · University of Washington (3) · Eisai Co., Ltd. (2) · National Cancer Institute (NCI) (2) · Alexander B Olawaiye, MD (1) · Eastern Cooperative Oncology Group (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · The University of Texas Health Science Center at San Antonio (1)
Often tested with
Tested in the same studies.
Cyclophosphamide (3) · Aldesleukin (2) · Etanercept (1) · Mycophenolic Acid (1) · Pentostatin (1) · Doxorubicin (1) · Vincristine (1) · Prednisone (1)
Studies
Open first, then newest update. How each study uses denileukin diftitox is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 39
- Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/2Masonic Cancer Center, University of MinnesotaNCT04855253Written as E7777How we know
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid TumorsActive, not recruitingPhase 1/2Alexander B Olawaiye, MDNCT05200559Written as E7777How we know
- A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaCompletedPhase 3Eisai Inc.NCT01871727Written as E7777 9 mcg/kgHow we know
- Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaCompletedPhase 2Eastern Cooperative Oncology GroupNCT00003615Written as denileukin diftitoxHow we know
- Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV MelanomaTerminatedPhase 1/2Fred Hutchinson Cancer CenterNCT00945269Written as denileukin diftitoxHow we know
- Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV MelanomaCompletedPhase 2Eisai Inc.NCT01127451Written as Denileukin diftitoxHow we know
- Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)CompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT00224874Written as Denileukin DiftitoxHow we know
- Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell LymphomaCompletedPhase 2Eisai Co., Ltd.NCT02676778Written as E7777How we know
- Vaccination Plus Ontak in Patients With Metastatic MelanomaTerminatedPhase 2University of ChicagoNCT00515528Written as OntakHow we know
- Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)TerminatedPhase 2University of California, San FranciscoNCT00632827Written as Denileukin diftitoxHow we know
- A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell LymphomaCompletedPhase 2Eisai Inc.NCT00211185Written as Denileukin diftitoxHow we know
- Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell LeukemiaTerminatedPhase 2National Cancer Institute (NCI)NCT00117845Written as Denileukin diftitox (Ontak)How we know
- Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube CancerCompletedPhase 1University of WashingtonNCT00357448Written as denileukin diftitoxHow we know
- ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous TreatmentCompletedPhase 1/2University of WashingtonNCT00425672Written as ONTAKHow we know
- E7777 for the Treatment of Patients With Peripheral T-Cell LymphomaCompletedPhase 1Eisai Co., Ltd.NCT01401530Written as denileukin diftitox (E7777)How we know
- A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian CancerCompletedPhase 2The University of Texas Health Science Center at San AntonioNCT00880360Written as OntakHow we know
- Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous TransplantationTerminatedPhase 1Barbara Ann Karmanos Cancer InstituteNCT01251952Written as Denileukin Diftitox (Ontak)How we know
- Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's LymphomaCompletedPhase 2Alliance for Clinical Trials in OncologyNCT00460109Written as denileukin diftitoxHow we know
- Denileukin Diftitox in Treating Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedPhase 2Wake Forest University Health SciencesNCT00082940Written as denileukin diftitoxHow we know
- Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin LymphomaWithdrawnNot applicableUniversity of MiamiNCT00513188Written as denileukin diftitoxHow we know
See all 39 studies that test denileukin diftitox →
Given beside what is tested · 1 — denileukin diftitox is usual care or a partner of the new treatment
Codes
What other systems call denileukin diftitox · ClinicalTrials.gg INT003686
- MeSH (NLM) C078456denileukin diftitoxConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 25E79B5CTMDENILEUKIN DIFTITOXConfirmed FDA, NLM, Wikidata
- RxNorm 214470One source FDA
- Wikidata Q1187179denileukin diftitoxConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1476Denileukin DiftitoxOne source FDA
- DrugBank DB00004One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C078456 | denileukin diftitox | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 25E79B5CTM | DENILEUKIN DIFTITOX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 214470 | — | One source FDA |
| Wikidata | Q1187179 | denileukin diftitox | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1476 | Denileukin Diftitox | One source FDA |
| DrugBank | DB00004 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.